Industry·July 21, 2026

Novo Nordisk Sues Eli Lilly Over Obesity Drug Advertising Claims

Novo Nordisk has filed a lawsuit against Eli Lilly alleging misleading advertising of Lilly's GLP-1 obesity medications. The suit, which follows a cease-and-desist demand, claims Lilly is using deceptive advertisements to portray its products as broadly superior to Novo's competing medicines. Lilly has responded that its marketing campaign is truthful. The legal action comes as both manufacturers compete intensively in the rapidly growing obesity treatment market.

Why it matters

GLP-1 drug competition directly affects Medicaid managed care pharmacy spend, formulary positioning, and prior authorization protocols as states and plans navigate coverage decisions for high-cost obesity treatments.

Pharmacy · Managed Care

Read the full article at healthcaredive.com →

Share this briefing